Mood Disorders

AXS-05 (Dextromethorphan-Bupropion) Significantly Improved Functioning in Major Depressive Disorder: Analysis of the Domains of the Sheehan Disability Scale

Major Depressive Disorder carries a substantial economic burden and personal impairment to those it affects. In the GEMINI and COMET trials, AXS-05 demonstrated substantial improvements i...

Andrew J. Cutler , MD;

10/26/2023

Adjunctive Brexpiprazole in Patients With Major Depressive Disorder Including in a Subgroup With Energy/Concentration Symptoms: Time to Efficacy Onset

This post hoc pooled analysis of three randomized, fixed-dose, 6-week studies explored time to efficacy onset of adjunctive brexpiprazole 2–3 mg/day in patients with major depressive diso...

Shivani Kapadia ;

10/26/2023

Adjunctive Brexpiprazole in Patients With Major Depressive Disorder Who Had One Prior Inadequate Antidepressant Including in a Subgroup With Energy/Concentration Symptoms

This post hoc pooled analysis of three randomized, fixed-dose, 6-week studies explored the efficacy of adjunctive brexpiprazole 2–3 mg/day in patients with major depressive disorder who h...

Shivani Kapadia ;

10/26/2023

Adjunctive Cariprazine in Patients With Major Depressive Disorder: A Post Hoc Analysis of Efficacy and Safety by Background Antidepressant Therapy

In this post hoc analysis, data from a phase 3 trial were used to evaluate adjunctive cariprazine versus adjunctive placebo by background ADT in patients with MDD and inadequate response ...

Majid Kerolous , PharmD, MPH;

10/26/2023

Aripiprazole Once-Monthly for the Treatment of Adult Patients in the Earlier Stages of Bipolar I Disorder – a Post Hoc Analysis of Data From a Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Trial

This post hoc analysis of data from a double-blind, placebo-controlled, 52-week randomized-withdrawal trial (NCT01567527) was conducted to evaluate the efficacy of aripiprazole once-month...

Karimah S. Bell Lynum , PharmD, MBA, BCPP;

10/26/2023

Assessment of Withdrawal Symptoms after Discontinuation of AXS-05 (Dextromethorphan-Bupropion) Treatment: Results from the GEMINI Trial

The GEMINI trial evaluated withdrawal symptoms in MDD patients after a 6-week treatment with AXS-05. Upon discontinuation, symptoms were assessed using the PWC-20. Results showed no signi...

Matthew J. Baker , PharmD;

10/26/2023

Association between Anhedonia Severity and Clinical and Humanistic Outcomes Among US Adults with Major Depressive Disorder

This study examined the association of anhedonia severity with health-related outcomes among adults with major depressive disorder (MDD). The results showed that higher anhedonia scores w...

Tiina Drissen , PhD;

10/26/2023

Derail Depression: Assessing the Effectiveness of a Continuing Education Quality Improvement Program

Abstract: Nearly 15 million adults in the US have experienced one or more major depressive disorder (MDD) events in the past year; primary care clinicians are the first line for initial d...

Rachel Deerr ;

Lesley Simon ;

01/19/2023

Depression and Anxiety in Medical Students during the 2020 COVID-19 Pandemic

Abstract: Medical students are prone to anxiety and depression, largely due to the nature of their coursework. During the COVID-19 pandemic, many medical students were required to study f...

Karthika Nair ;

Tiffany Joseph ;

01/19/2023

Bipolar Disorder Across the Spectrum: Novel Screening Tools and Treatment Options

Bipolar disorder, previously known as manic depression, is a serious mental illness associated with extreme mood swings and manic/hypomanic episodes that interfere with an individual’s ab...

James Sonne ;

01/19/2023